3 results
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMOCompleted
To analyse the safety of oestradiol in the setting of endocrine treatment for locally extended prostate cancer adjuvant to radiotherapy.
Approved WMOCompleted
To investigate whether early treatment with levodopa has a delayed beneficial effect on PD symptoms and functional health, and improves the ability to (maintain) work, reduces the use of (informal) care, caregiver burden, and costs. Additionally,…